Our faculty author, co-author and contribute to more than 1500 peer-reviewed scientific publications each year. Find their recent publications below, and filter by division.
Search the faculty directory to find an individual's list of publications.
Publications
Ashley, D. M., A. Muscat, L. Rigby, and E. Algar. “EXPLORING THE FEASIBILITY OF EPIGENETIC THERAPIES FOR RHABDOID TUMOR.” In Neuro Oncology, 12:II36–II36. OXFORD UNIV PRESS INC, 2010.
Partap, S., T. V. Hoc, T. T. Ha, and D. Ashley. “IDENTIFYING OBSTACLES IN TREATING CHILDREN WITH PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS IN DEVELOPING COUNTRIES.” In Neuro Oncology, 12:II18–II18. OXFORD UNIV PRESS INC, 2010.
Lei, Dapeng, Erich M. Sturgis, Li-E Wang, Zhensheng Liu, Mark E. Zafereo, Qingyi Wei, and Guojun Li. “FAS and FASLG genetic variants and risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck.” Cancer Epidemiol Biomarkers Prev 19, no. 6 (June 2010): 1484–91. https://doi.org/10.1158/1055-9965.EPI-10-0030.
PMID
20501759
Tailor, Tina D., Gabi Hanna, Pavel S. Yarmolenko, Matthew R. Dreher, Allison S. Betof, Andrew B. Nixon, Ivan Spasojevic, and Mark W. Dewhirst. “Effect of pazopanib on tumor microenvironment and liposome delivery.” Mol Cancer Ther 9, no. 6 (June 2010): 1798–1808. https://doi.org/10.1158/1535-7163.MCT-09-0856.
PMID
20515941
Armstrong, Andrew J., George J. Netto, Michelle A. Rudek, Susan Halabi, David P. Wood, Patricia A. Creel, Kelly Mundy, et al. “A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.” Clin Cancer Res 16, no. 11 (June 1, 2010): 3057–66. https://doi.org/10.1158/1078-0432.CCR-10-0124.
PMID
20501622
Ostrander, JH, McMahon, CM, Lem, S, Millon, SR, Brown, JQ, Seewaldt, VL, and Ramanujam, N. "Optical redox ratio differentiates breast cancer cell lines based on estrogen receptor status." Cancer Res 70, no. 11 (June 1, 2010): 4759-4766.
PMID
20460512
Khasraw, M., N. Pavlakis, S. McCowatt, C. Underhill, S. Begbie, P. de Souza, A. Boyce, et al. “Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer.” Ann Oncol 21, no. 6 (June 2010): 1302–7. https://doi.org/10.1093/annonc/mdp524.
PMID
19917571
Armstrong, A. J., and D. J. George. “Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.” Prostate Cancer Prostatic Dis 13, no. 2 (June 2010): 108–16. https://doi.org/10.1038/pcan.2009.62.
PMID
20066005
Khasraw, M., A. Townsend, T. Price, J. Hart, D. Bell, and N. Pavlakis. “Objective radiological disease control with sandostatin monotherapy in metastatic neuroendocrine tumours.” Intern Med J 40, no. 6 (June 2010): 453–58. https://doi.org/10.1111/j.1445-5994.2010.02245.x.
PMID
20636828
Khasraw, M., L. E. Abrey, A. B. Lassman, A. Hormigo, C. Nolan, I. T. Gavrilovic, I. K. Mellinghoff, A. S. Reiner, L. M. DeAngelis, and A. M. Omuro. “Phase II trial of continuous low-dose temozolomide (TMZ) for recurrent malignant glioma (MG) with and without prior exposure to bevacizumab (BEV).” In Journal of Clinical Oncology, 28:2065–2065. American Society of Clinical Oncology (ASCO), 2010. https://doi.org/10.1200/jco.2010.28.15_suppl.2065.